Latest Period
Q1 2026
Security Snapshot
Dianthus Therapeutics, Inc. /DE/ - Common Stock, $0.001 par value per share (DNTH) Institutional Ownership
CUSIP: 252828108
13F Institutional Holders and Ownership History from Q3 2023 to Q1 2026
Institutions Reporting
239
Shares (Excl. Options)
61,200,715
Price
$83.92
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.
- Security type / class
- Equity / Common Stock, $0.001 par value per share
- Symbol
- DNTH on Nasdaq
- Shares outstanding
- 54,411,104
- Reported price per share
- $86.15
- Price from insider filings
- $86.15
- All holders as of 31 Mar 2026
- Q1 2026
- Total 13F shares
- 61,200,715
- Total reported value
- $5,135,825,058
- Portfolio coverage rank
- 0.01%
- Share change
- +12,750,077
- Value change
- +$1,101,913,534
- Number of holders
- 239
Security identity
Issuer context
Latest holder snapshot
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors
Key facts
- DNTH - Dianthus Therapeutics, Inc. /DE/ - Common Stock, $0.001 par value per share is tracked under CUSIP 252828108.
- 239 institutions reported positions in Q1 2026.
- 13 significant owners is listed from Schedule 13D/13G reporting.
Change
- Holder count moved from 167 to 239 between Q4 2025 and Q1 2026.
- Reported value moved from $2,024,311,315 to $5,135,825,058.
Research use
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Evidence
Source: SEC Form 13F
Open SEC Evidence
Latest holder context comes from 239 institutions filings for Q1 2026.
Security key
252828108
Latest holder period
Q1 2026
13F holders
239
13D/G owners
13
CIK / CUSIP context first
Open Q1 2026 holders
DNTH full holder history
Dianthus Therapeutics, Inc. /DE/ SEC filings
Dianthus Therapeutics, Inc. /DE/ company facts
Dianthus Therapeutics, Inc. /DE/ insider transactions
Broader feeds
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 252828108:
13D/G owners
Significant owners
Large-stake holder rows connected to Schedule 13D/G evidence.
Rows
13
Security
DNTH
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| FMR LLC | 15% | +7.1% | $234,944,605 | +$58,553,941 | 5,970,638 | +33% | FMR LLC | 30 Sep 2025 |
| Sirenia Capital Management LP | 5.3% | $256,475,863 | 2,798,122 | Sirenia Capital Management LP | 31 Mar 2026 | |||
| BlackRock, Inc. | 5.1% | +2% | $221,045,616 | +$86,760,776 | 2,634,004 | +65% | BlackRock, Inc. | 31 Mar 2026 |
| RA CAPITAL MANAGEMENT, L.P. | 4.8% | -20% | $239,391,447 | 2,611,733 | 0% | RA Capital Management, L.P. | 31 Mar 2026 | |
| WELLINGTON MANAGEMENT GROUP LLP | 4.8% | -24% | $237,929,470 | +$1,660,971 | 2,595,783 | +0.7% | Wellington Management Group LLP | 31 Mar 2026 |
| Fairmount Funds Management LLC | 4.9% | -50% | $72,191,285 | -$64,524,950 | 2,139,635 | -47% | Fairmount Funds Management LLC | 21 Nov 2025 |
| Avidity Partners Management LP | 4.9% | -50% | $70,995,168 | -$43,010,234 | 2,104,184 | -38% | Avidity Partners Management LP | 17 Nov 2025 |
| Octagon Capital Advisors LP | 3.6% | -42% | $178,431,497 | -$43,080,200 | 1,946,667 | -19% | Octagon Capital Advisors LP | 31 Mar 2026 |
| TCG Crossover GP II, LLC | 4.7% | $32,660,322 | 1,501,624 | TCG Crossover GP II, LLC | 31 Mar 2025 | |||
| BCLS Fund III Investments, LP | 3.1% | -55% | $51,780,350 | -$45,896,187 | 1,315,892 | -47% | BCLS Fund III Investments, LP | 30 Sep 2025 |
| Vestal Point Capital, LP | 3% | -70% | $46,433,000 | -$79,487,000 | 1,180,000 | -63% | Vestal Point Capital, LP | 30 Sep 2025 |
| Venrock Healthcare Capital Partners III, L.P. | 3.1% | $20,060,000 | 1,000,000 | Venrock Healthcare Capital Partners III, L.P. | 30 Jun 2025 | |||
| Point72 Asset Management, L.P. | 1.2% | -81% | $58,992,284 | -$214,307,954 | 643,599 | -78% | Point72 Asset Management, L.P. | 31 Mar 2026 |
As of 31 Mar 2026, 239 institutional investors reported holding 61,200,715 shares of Dianthus Therapeutics, Inc. /DE/ - Common Stock, $0.001 par value per share (DNTH). This represents 112% of the company’s total 54,411,104 outstanding shares.
13F concentration
Top 25 institutional shareholders
Largest 13F positions for this security by reported shares and value.
Top holder share
79%
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| FMR LLC | 14% | 7,767,686 | +21% | 0.03% | $651,864,210 |
| BlackRock, Inc. | 5.8% | 3,175,703 | +66% | 0% | $266,504,995 |
| RA CAPITAL MANAGEMENT, L.P. | 4.8% | 2,611,733 | +62% | 2.3% | $219,176,633 |
| WELLINGTON MANAGEMENT GROUP LLP | 4.8% | 2,595,783 | +3.7% | 0.04% | $217,838,110 |
| Fairmount Funds Management LLC | 4.7% | 2,537,191 | +19% | 15% | $212,921,069 |
| Avidity Partners Management LP | 3.9% | 2,104,184 | 0% | 35% | $176,583,121 |
| VANGUARD CAPITAL MANAGEMENT LLC | 3.7% | 2,031,249 | 0% | 0% | $170,462,416 |
| Octagon Capital Advisors LP | 3.6% | 1,946,667 | -19% | 18% | $163,364,295 |
| TCG Crossover Management, LLC | 3.1% | 1,676,624 | 0% | 4% | $140,702,286 |
| CITADEL ADVISORS LLC | 3% | 1,610,483 | +51% | 0.1% | $135,151,733 |
| STATE STREET CORP | 2.6% | 1,398,913 | -7.2% | 0% | $117,396,779 |
| T. Rowe Price Investment Management, Inc. | 2.4% | 1,292,182 | 0.07% | $108,440,000 | |
| Venrock Adviser, LLC | 2.2% | 1,180,000 | +18% | 3.7% | $99,025,600 |
| FRED ALGER MANAGEMENT, LLC | 2.1% | 1,161,923 | +3373% | 0.43% | $97,508,578 |
| PRICE T ROWE ASSOCIATES INC /MD/ | 2.1% | 1,146,948 | +86% | 0.01% | $96,253,000 |
| Polar Capital Holdings Plc | 2% | 1,076,009 | +7.1% | 0.39% | $90,298,675 |
| DEERFIELD MANAGEMENT COMPANY, L.P. | 1.9% | 1,019,813 | 1% | $85,582,707 | |
| FRANKLIN RESOURCES INC | 1.8% | 968,182 | +109% | 0.02% | $81,249,867 |
| Cormorant Asset Management, LP | 1.7% | 950,000 | 4% | $79,724,000 | |
| GEODE CAPITAL MANAGEMENT, LLC | 1.7% | 916,211 | +35% | 0% | $76,904,871 |
| BRAIDWELL LP | 1.7% | 899,364 | -29% | 2.5% | $75,474,627 |
| BAKER BROS. ADVISORS LP | 1.6% | 852,164 | +7.9% | 0.41% | $71,513,603 |
| FARALLON CAPITAL MANAGEMENT LLC | 1.5% | 836,000 | 0.46% | $70,157,120 | |
| UBS Group AG | 1.4% | 781,282 | +29% | 0.01% | $65,565,185 |
| SILVERARC CAPITAL MANAGEMENT, LLC | 1.2% | 654,746 | -13% | 6.5% | $54,946,284 |
Quarter history
Institutional holders across reporting periods
Holder count, reported shares/value, and median price by quarter.
Periods
11
Latest
Q1 2026
Rows shown
1-11 of 11
| Period | Reported Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q1 | 61,200,715 | $5,135,825,058 | +$1,101,913,534 | $83.92 | 239 |
| 2025 Q4 | 49,121,649 | $2,024,311,315 | +$67,678,158 | $41.21 | 167 |
| 2025 Q3 | 46,828,772 | $1,842,663,442 | +$358,133,968 | $39.35 | 140 |
| 2025 Q2 | 39,106,709 | $728,558,630 | +$24,440,177 | $18.63 | 101 |
| 2025 Q1 | 37,715,319 | $685,461,303 | +$43,246,773 | $18.14 | 97 |
| 2024 Q4 | 35,126,689 | $765,706,199 | +$63,092,353 | $21.80 | 94 |
| 2024 Q3 | 31,364,805 | $858,714,506 | +$44,837,092 | $27.38 | 90 |
| 2024 Q2 | 29,702,499 | $768,778,734 | +$87,583,327 | $25.88 | 74 |
| 2024 Q1 | 26,075,021 | $782,250,559 | +$479,966,613 | $30.00 | 75 |
| 2023 Q4 | 10,291,119 | $106,507,945 | +$518,588 | $10.40 | 38 |
| 2023 Q3 | 10,072,640 | $136,328,208 | +$136,328,208 | $13.67 | 30 |